Tenoten

Tenoten is a sedative, which, according to information from the official website of the drug, is indicated for all people with symptoms of anxiety. Everything about it is good: it relieves irritability, has no side effects, is not capable of overdose, does not make you sleepy and does not slow down the brain. True, there is no molecule of the active substance in it - homeopathy after all.

It is produced by the Materia Medica holding, which is managed by meme scientist Oleg Epstein. He changed the packaging of homeopathic medicines and called them “release-active” (without changing the preparation method, btw). This development in 2021 received an anti-award “For the most harmful pseudoscientific project” from the Ministry of Education and Science of the Russian Federation. And in 2019, the Russian Academy of Sciences stated that the idea of release activity contradicts biological, physical and chemical fundamental laws.

But things are getting muddy, money is swirling, so Materia Medica produces homeopathy (Tenoten, Anaferon, Ergoferon, Impaza, Rengalin and others), which millions of Russians are taking advantage of. Although the placebo effect was not canceled.

What is inside

Tenoten is prescribed for anxiety disorders, neuroses, phobias, personality and behavioral disorders caused by brain injuries (wow, they swung), and other mental health disorders.

The main stress relievers in Tenoten are antibodies to the brain-specific protein S100. Sounds solid, let's figure it out. S100 is a family of proteins that do many different things inside and outside the cell. For example, they support calcium metabolism and participate in cell growth and specialization. Some members of the family may be a nonspecific marker of tumor (melanoma, neurofibroma, sarcoma) and inflammatory diseases (psoriasis). Brain-specific means that these family members are synthesized by nerve cells in the brain. But why them? Are there studies that support the involvement of the brain-specific S100 protein in the stress response? Nope. In general, it looks like they took a random protein.

Antibodies are also proteins that protect the body from colonization by pathogens themselves or press an alarm button that activates other pathways of the immune response. That is, antibodies to the brain-specific protein S100 should kill this very protein. But he’s such a good guy, why??? Idk. We did not find any justification for choosing this particular protein to reduce stress and “even out mood.”

Why should it work?

This is what is written about the mechanism on the official website: “The effect is realized by stabilizing the physiological mechanisms of brain functioning, optimizing metabolic processes and transmitting nerve impulses.” Has it become clearer? And also: “modifies the functional activity of the S100 protein” (what kind of modifications does the killer antibody carry out?), “increases the activity of stress-limiting systems,” “promotes the restoration of neuronal plasticity processes.”

Okay, it's all blah blah. How does he do it? Guys, you are going to die. In the instructions in the “Pharmacokinetics” section, which should describe what happens to the substance in the body, there is the following:

“The sensitivity of modern physicochemical methods of analysis does not allow us to assess the content of the active substance of the drug Tenoten in biological fluids, organs and tissues due to the specific composition of the drug, which makes it technically impossible to study pharmacokinetics.”

That is, the instructions say that the manufacturer does not know what happens to Tenoten in the body, how it is excreted, what systems it enters, and therefore how it works.

Use of the drug Tenoten in clinical practice

In modern neurology and psychiatry, psychotropic drugs are actively used to suppress anxiety, fear, restlessness, emotional stress or reduce the severity of these symptoms. The article provides an overview of studies on the effectiveness and safety of the use of the drug Tenoten in the treatment of concomitant anxiety-depressive disorders, a new generation anxiolytic that has a wide spectrum of action (antidepressive, nootropic, neuroprotective, etc.) and does not cause side effects. Tenoten is actively used in neurological, psychiatric and somatic practice, in particular, for psychovegetative disorders, dyscirculatory encephalopathy of I–II degrees, cerebrovascular insufficiency in elderly patients, anxiety disorders, etc.

There is a relationship between the development of anxiety, depressive and other neurotic disorders and the brain-specific protein S100, which is expressed and secreted by microglial cells and astrocytes. The S100 protein plays an important role in the implementation of the basic functions of the neural systems of the brain, such as the generation and conduction of nerve impulses, regulation of synaptic and metabolic processes, proliferation and differentiation of neurons and glial cells. In this regard, a promising direction in the treatment of neurotic disorders is the use of drugs that regulate the activity of the S100 protein. The use of antibodies to the S100 protein appears to be a fundamentally new method of regulatory influence. The drug Tenoten contains ultra-low doses of affinity-purified antibodies to S100 [13]. Tenoten modifies the functional activity of the S100 protein, which ensures the neurotrophic effect of the drug, promotes the restoration of neuronal plasticity processes, and prevents the development of neurotic and neurosis-like conditions [13]. The neurotrophoprotective effect of Tenoten, especially pronounced in conditions of intoxication and hypoxia of the central nervous system, the absence of a sedative and muscle relaxant effect, and compatibility with other drugs make the drug promising for the relief of neurotic symptoms accompanying various somatic diseases. The pharmacological effects of Tenoten also include a stress-protective effect, regulation of the energy metabolism of neurons, and an effect on the proliferation and differentiation of brain cells. In addition, Tenoten has a wide spectrum of psychotropic, neurotropic, and vegetative modulating activity [13]. By interacting with the GABA-A-benzodiazepine receptor complex, Tenoten has a GABA-mimetic effect. The drug does not cause lethargy, daytime sleepiness, muscle relaxation, dependence and associated withdrawal syndrome even with long-term therapy, therefore it can be used in people leading an active lifestyle, drivers, etc. [13]. Indications for use of Tenoten are:

neurotic and neurosis-like conditions, psychosomatic diseases;
stress disorders with increased nervous tension, irritability, anxiety and autonomic reactions;
moderately expressed organic lesions of the central nervous system, including those of traumatic and dyscirculatory origin, accompanied by instability of the emotional background, irritability, memory loss, and autonomic disorders.

It should be noted that for each of the areas of application of Tenoten, research is being conducted in several regions of Russia by independent research teams, which undoubtedly increases the reliability of the results obtained.

Use of the drug Tenoten in neurological practice

Tenoten in the treatment of psychovegetative disorders

About a third of patients with autonomic and anxiety disorders seek help from therapists. Diagnosis of such conditions does not cause difficulties, unlike the choice of rational treatment. The effectiveness of using the drug Tenoten in the treatment of psychopathological and vegetative symptoms was studied in Clinical Hospital No. 83 of the FMBA of Russia (Moscow). The study involved 2 groups of patients: patients in the main group, in addition to basic therapy, were prescribed Tenoten 2 tablets 3 times a day (duration 4 weeks), patients in the control group received only basic therapy. The main group included 40 patients aged 30–60 years with autonomic dysfunction syndrome (psychovegetative paroxysms, tension headaches (TTH), anxiety-depressive syndrome) and organic diseases of the central nervous system (dyscirculatory encephalopathy (DEP) stages I–II in combination with anxiety-depressive syndrome). The control group consisted of 20 patients aged 30–60 years with diagnoses of DEP and tension-type headache. To study the dynamics of the patients' condition at the beginning and after treatment, the level of anxiety and depression was assessed using neurological and psychological research methods, as well as an integral assessment of the current functional state of the body using the Telecard device, which records vegetative indicators using an ECG. Clinically, all patients complained of feelings of anxiety and decreased mood, sleep disturbance, pain of various localizations, increased fatigue, and high levels of reactive and personal anxiety. By the end of the 4th week of Tenoten therapy, these complaints regressed, and a significant decrease in the level of reactive and personal anxiety was noted in comparison with the control group. According to cardiointervalography data, before the start of treatment, the patients were found to have excessive autonomic activation in both the ergotropic and parasympathetic circuits, which indicated an unstable autonomic status and tension in the autonomic system. After 1 week of therapy, indicators of autonomic reactivity in the ergotropic circuit changed the most in patients taking Tenoten, in contrast to patients in the control group. The study showed that Tenoten in a dosage of 2 tablets 3 times a day already by the end of the 1st week has a vegetative-stabilizing effect, and by the end of the 4th week it has a pronounced anti-anxiety effect [15].

Tenoten in the complex therapy of transient cerebrovascular accidents

In patients who have suffered a transient cerebrovascular accident (TCI), the restoration of functional activity occurs 2 times slower if there are disturbances in the emotional sphere. An open comparative clinical and pharmacological study to assess the effectiveness and safety of Tenoten in the treatment of anxiety disorders in patients with PMN was conducted at the Central Clinical Hospital No. 1 of the Ural State Medical Academy (Ekaterinburg). 60 patients who underwent PNMC were examined; the average age was 42.1 ± 2.5 years. Patients were divided into 2 groups: patients in the main group (n = 31) took Tenoten, patients in the control group (n = 29) took Phenazepam.

Before and after treatment, the level of anxiety and depression was assessed using neurological and psychological research methods. The study recorded a significant decrease in the level of anxiety and depression. After stopping Tenoten, no patient clinically or subjectively experienced withdrawal syndrome in the form of increased anxiety and worsening mood, while withdrawal of Phenazepam may be accompanied by decreased mood, increased irritability, and sleep disturbances. The study showed that the anti-anxiety effect of Tenoten in patients with PNMC is comparable to the effect of the typical benzodiazepine drug Phenazepam. However, unlike the latter, Tenoten does not cause side effects and is better tolerated by patients. That is why Tenoten can be recommended for the treatment of patients with PNMC accompanied by anxiety and mild depressive disorders [1].

Tenoten in complex therapy of patients with DEP I–II degrees

One of the common reasons for a decrease in the quality of life of patients with chronic cerebrovascular pathology (CVP) is psychological distress, manifested by emotional disturbances in the form of anxiety and depression. The high percentage of disability, frequent complications, and low effectiveness of treatment for many CVP syndromes are largely explained not only by the progression of focal neurological symptoms, but also by emotional disorders. An assessment of the effectiveness of the use of Tenoten in the treatment of anxiety and depression in patients with chronic CVP was carried out on the basis of the neurological department of ICH No. 1 (Novosibirsk). Patients with grade I–II DEP were divided into 2 groups of 30 people. In the main group (average age 65 ± 9 years), in addition to basic therapy, Tenoten (2 tablets 3 times a day) was prescribed for 8 weeks. Patients in the control group (average age 60 ± 10 years) took drugs that improve cerebral circulation. To study the dynamics of the patients' condition at the beginning and after treatment, the level of anxiety and depression was assessed using clinical (changes in blood pressure (BP)) and psychological research methods. After 8 weeks of therapy with Tenoten, positive dynamics of blood pressure levels and general psychological well-being were observed, and a decrease in the severity of depressive episodes and anxiety disorders was noted. Thus, the data obtained allow us to recommend Tenoten in the treatment of anxiety and depressive conditions in patients with grade I–II DEP [3].

Tenoten in the complex treatment of anxiety in elderly patients with cerebrovascular insufficiency

Due to the fact that elderly patients are more sensitive to the side effects of psychotropic drugs, the Russian Gerontological Research and Clinical Center (Moscow) conducted a comparative study of the clinical effectiveness and tolerability of Tenoten and Cavinton in inpatient conditions in patients with organic pathology of the central nervous system. We examined 50 patients diagnosed with DEP due to cerebral atherosclerosis, consequences of acute cerebrovascular accidents and post-traumatic encephalopathy. The patients were divided into 2 groups: the main group (n = 30, average age 73.5 ± 2.1 years) received Tenoten 1 tablet 3 times a day against the background of basic therapy, the comparison group (n = 20, average age 75, 5 ± 1.8 years) – Cavinton 5 mg 3 times a day. The course of treatment is 28 days. The dynamics of subjective complaints, neurodynamic indicators, cognitive functions, and anxiety levels were assessed. The study noted positive dynamics in the subjective assessment of patients, an increase in the speed of movements in the hands, a decrease in the average time for performing a test for volume and switching of attention, memorizing 10 words and serial counting, and a significant decrease in the level of anxiety. A study of the clinical effectiveness of Tenoten showed that the drug can be recommended in gerontological practice in elderly patients with DEP as a means of improving cognitive function and having a pronounced anti-anxiety effect [11].

Use of the drug Tenoten in the treatment of somatic diseases

Patients with increased anxiety visit a cardiologist 6 times more often, a rheumatologist 2.5 times more often, a neurologist, urologist and ENT doctor 2 times more often, a gastroenterologist 1.5 times more often, and 1.5 times more often seek help from hospital In addition, their ability to work is reduced by 2–2.5 times. The prevalence of neurotic and somatoform disorders with anxiety symptoms in patients with arterial hypertension (AH) can reach 51.3%.

Tenoten in complex therapy of patients with diseases of the cardiovascular system

On the basis of the Medical and Sanitary Unit No. 25 of the Novosibirsk State Medical University, a study was conducted to assess the effectiveness and tolerability of combined treatment with antihypertensive drugs and the anti-anxiety drug Tenoten in patients with hypertension. The study involved 60 patients with hypertension (average age 61.41 ± 6.91 years), average disease duration – 10.61 ± 4.1 years. The patients were divided into two groups: the main group (n = 30) included patients with stage II–III hypertension who received Tenoten as part of basic therapy; The control group (n = 30) included patients with moderate hypertension who took antihypertensive drugs. Tenoten was prescribed for 1 month according to the following regimen: 6 tablets per day for the first 2 weeks, and then 1 tablet 3 times a day for another two weeks. The level of anxiety and blood pressure indicators were assessed before prescribing drugs, after 2 and 4 weeks of therapy. During Tenoten therapy, the level of anxiety decreased in the 2nd week, and blood pressure values significantly decreased by the end of the 4th week. Thus, we can conclude that the inclusion of Tenoten in the complex therapy of patients with hypertension increases the effectiveness of the treatment and promotes a more rapid onset of the hypotensive effect [7].

On the basis of the clinic of propaedeutics of internal diseases of the St. Petersburg State Medical University. acad. I.P. Pavlov conducted a comparative randomized study of the clinical effectiveness and safety of the drugs Tenoten and Grandaxin (tofisopam) in the treatment of anxiety disorders of a neurotic level in patients with diseases of the cardiovascular system. The patients were divided into 2 groups: the Tenoten group (n = 31) and the Grandaxin group (n = 20). Tenoten was prescribed 1 tablet 3 times a day, Grandaxin - 50 mg 2 times a day, the course of treatment was 4 weeks. All patients were therapeutically examined; at 1, 2, 4 weeks of treatment and 4 weeks after discontinuation of drugs, the level of anxiety and general clinical symptoms were assessed. During Tenoten therapy, a more pronounced reduction in anxiety and somatic symptoms (BP dynamics) was noted than in the Grandaxin group, and a positive assessment of the overall clinical impression was given. The spectrum of effects of Tenoten in comparison with Grandaxin on anxiety symptoms in patients with heart disease turned out to be more uniform, the stability of the clinical effect was more pronounced [2].

The effectiveness and tolerability of combination therapy with antiarrhythmic drugs and Tenoten in patients with coronary heart disease (CHD) with extrasystole and paroxysmal supraventricular tachyarrhythmias were assessed. On the basis of City Clinical Hospital No. 20 named after. I.S. Berzon (Krasnoyarsk) examined 60 patients with coronary artery disease, angina pectoris I–III functional class (FC), and cardiac arrhythmias aged from 42 to 79 years. The patients were divided into 2 groups: in the main group (n = 30, average age 64.4 ± 8.6 years), patients took Tenoten as part of basic therapy; in the control group (n = 30, average age 63.1 ± 8.5 years) – only antiarrhythmic therapy. Tenoten was prescribed at a dose of 2 tablets 3 times a day, after a week the dose of the drug was reduced to 3 tablets a day. The patients' condition was analyzed after 4 and 8 weeks using a physical examination method, blood pressure measurement, ECG, Holter monitoring and anxiety level assessment. According to the data obtained, in patients with coronary artery disease, angina pectoris class I–III and cardiac arrhythmias, Tenoten had a pronounced anti-anxiety effect. A positive antiarrhythmic effect (disappearance of paroxysmal atrial tachyarrhythmias and a decrease in the daily number of extrasystoles by at least 75%) was observed in 80% of patients in the main group and in 53.3% of the control group. Positive dynamics of the FC of angina pectoris were obtained, a decrease in the number and duration of episodes of myocardial ischemia (by at least 50% of the initial data) in the clinical picture of IHD was noted in 60% of cases in the main group and in 33.3% in the control group. Thus, the appointment of Tenoten in combination therapy for patients with diseases of the cardiovascular system not only has a pronounced anti-anxiety effect, but also improves the course of coronary artery disease, reducing the manifestations of angina pectoris, and also helps to normalize the heart rhythm [5].

Similar results were obtained in a comparative study of the effectiveness and tolerability of combination therapy with antihypertensive drugs and the drug Tenoten and therapy with antihypertensive drugs in combination with the benzodiazepine drug Clonazepam in patients with hypertension. The study included 60 patients from cardiology hospitals of the First Moscow State Medical University named after. THEM. Sechenov and the Institute of Clinical Cardiology named after. A.L. Myasnikov with various diseases of the cardiovascular system. The therapeutic diagnosis was determined taking into account the nature of heart rhythm disturbances:

IHD, angina pectoris II–III FC, arterial hypertension II–III stage;
postmyocardial cardiosclerosis;
dyshormonal myocardial dystrophy;
rheumatism, inactive phase, combined heart defects with various heart rhythm disturbances (sinus tachycardia, ventricular and supraventricular extrasystoles, paroxysmal atrial fibrillation, paroxysmal atrial fibrillation, paroxysmal atrial fibrillation, permanent atrial fibrillation).

All patients were diagnosed with anxiety spectrum disorders. Patients were divided into 3 groups:

30 people (average age 54.1 ± 5.2 years) received Tenoten 2 tablets 3 times a day;
20 people (mean age 59.2 ± 5.1 years) took Clonazepam (0.5–1 mg per day);
10 people (mean age 57.9 ± 4.8 years) received only somatotropic therapy.

The duration of treatment with Tenoten and Clonazepam was 28 days. The condition was assessed at the beginning, on the 14th and 28th days of therapy, taking into account the dynamics of the level of anxiety, depression and functional disabilities. After 4 weeks of therapy, the indicators changed significantly in the Tenoten and Clonazepam groups. When studying the somatic state of patients (in particular, the results of 24-hour Holter monitoring), all patients noted a subjective improvement in their well-being and a decrease in the intensity of hypochondriacal reactions. During the study, 5 patients taking Clonazepam at the beginning of treatment experienced a slight slowdown in mental and motor reactions, a feeling of fatigue, lethargy, and daytime drowsiness. In patients taking Tenoten, these undesirable side effects were not detected. After discontinuation of the drug at the end of the study for a week, not a single patient clinically or subjectively experienced withdrawal syndrome in the form of increased anxiety and deterioration of somatic condition. Thus, the appointment of Tenoten is possible in the treatment of anxiety neurotic disorders in patients with diseases of the cardiovascular system, in particular, with rhythm disturbances of various etiologies. It should be noted that the psychopharmacological value of Tenoten increases significantly due to the absence of side effects and the likelihood of developing dependence on the drug, which is extremely important for cardiac patients [8].

Tenoten in complex therapy of patients with gastrointestinal diseases

Currently, peptic ulcer disease is generally considered to be a multifactorial psychosomatic disease, in the pathogenesis of which emotional and psychosocial factors play a significant role. A study was conducted to assess the dynamics of the level of anxiety during Tenoten therapy in patients with Helicobacter pylori-associated duodenal ulcer. 102 patients of the gastroenterological department of the clinic of the State Research Institute of Medical Problems of the North of the Siberian Branch of the Russian Academy of Medical Sciences (Krasnoyarsk) were examined. Patients were divided into 2 groups: patients in the main group (n = 49, age 42.3 ± 2.81 years) took Tenoten 2 tablets 3 times a day for 3 weeks, in the control group (n = 53, age 41, 8 ± 2.36 years) patients received basic therapy. The dynamics of the condition were assessed based on the results of a study of the level of anxiety, determination of the size of the ulcerative defect during esophagogastroduodenoscopy, and a decrease in the incidence of pain in the epigastric region on the 10th and 20th day from the start of therapy. During therapy with Tenoten, a direct correlation was revealed between a decrease in the level of anxiety and the frequency of pain in the epigastric region. In the group of patients taking Tenoten, already on the 10th day from the start of therapy, more pronounced changes in indicators were noted, which significantly differed by the 20th day. Thus, the prescription of Tenoten as a complex therapy drug in patients with duodenal ulcer promotes positive clinical dynamics in the healing of ulcerative defects [14].

The effectiveness of Tenoten as a means of secondary prevention of relapses of duodenal ulcer (DU) was studied at the Department of Faculty Therapy of Surgut State University. The study involved 25 patients with chronic gastroduodenitis (CGD) and DU in the stage of unstable remission with annual seasonal exacerbations aged 20–59 years, the average duration of the disease was 11.3 ± 8.5 years, the average duration of residence in the North was 24. 1 ± 11.1 years. Tenoten was prescribed 1 tablet 2 times a day for a month (July – August) for the purpose of secondary prevention of autumn relapses. The effectiveness of Tenoten therapy was assessed based on the dynamics of the level of anxiety; the state of autonomic regulation was assessed using analysis of heart rate variability according to cardiointervalogram data. Analysis of the dynamics of clinical symptoms showed that as a result of the course of treatment, the frequency of complaints of intestinal dyspepsia, heartburn, pain and discomfort in the epigastric region significantly decreased. During therapy with Tenoten, a significant decrease in the severity of anxiety and a significant increase in the proportion of low-frequency heart rate waves, reflecting an increase in sympathetic activity, were noted. Spectral analysis of the active orthostatic test in the group of treated patients showed an adequate increase in sympathetic tone by 1.06 times and a decrease in parasympathetic influence by 1.76 times. As a result of the course of treatment with Tenoten, the studied parameters stabilized. Annual prophylactic use of the drug Tenoten as an additional anti-relapse agent helps to increase the duration and quality of remission of chronic gastroduodenitis and duodenal ulcer. Dispensary observation of patients with DU and CGD during the first year after preventive treatment with Tenoten showed that the number of clinical exacerbations (relapses) among patients in this group decreased by 2.4 times, and hospitalizations by 5 times. The appointment of Tenoten in the complex therapy of CGD and PUD helps to reduce the level of anxiety, stabilize autonomic homeostasis, reduce the severity of clinical symptoms and consolidate remission [4].

A clinical study was conducted on the effect of the drug Tenoten on the reduction of anxiety symptoms in patients with hypomotor biliary dyskinesias. At the Department of Therapy and Clinical Pharmacology of the St. Petersburg Medical Academy of Postgraduate Education, 41 patients were examined. Two groups were compared: patients in the main group (n = 21, average age 41 years) took Tenoten, patients in the control group (n = 20, average age 35 years) received basic therapy. Tenoten was prescribed 2 tablets 3 times a day, duration of administration was 1 month.

In order to study the dynamics of the patients' condition at the beginning of therapy and after 1 month of taking Tenoten, the level of anxiety and asthenia was assessed, as well as a subjective assessment of the effectiveness of therapy using a visual analogue scale. In addition to a significant reduction in the level of anxiety and depression, Tenoten’s effect on motor skills was noted, which was reflected in a decrease in dyskinetic phenomena while simultaneously increasing the contractility of the gallbladder and reducing the severity of pain, which makes it possible to recommend it for functional motor disorders of the cholangiopancreaticoduodenal zone [12].

Similar data assessing the effectiveness of Tenoten in the treatment of asthenodepressive disorders in 85 patients with cholelithiasis and irritable bowel syndrome were obtained during a study at the gastroenterology department of Kazan State Medical University. The authors came to the conclusion that the inclusion of Tenoten in complex therapy for diseases of the digestive tract will make it possible to carry out treatment much more effectively, restore ability to work in a shorter time and improve the quality of life of patients [6].

Use of the drug Tenoten in the treatment of neurotic disorders

At the Research Institute of Mental Health of the Siberian Branch of the Russian Academy of Medical Sciences (Tomsk), a study was conducted on the clinical effectiveness of Tenoten in outpatient settings in patients with neurotic disorders and people with pre-neurotic conditions. 47 patients were examined, of which the main group consisted of 22 patients (average age 42.7 ± 3.7 years) with neurotic disorders undergoing treatment at the Interdepartmental Center of the Scientific Research Institute of Mental Health of the Siberian Branch of the Russian Academy of Medical Sciences, the other group - 25 patients (average age 40.1 ± 5.2 years) with preneurotic conditions. In the group with neurotic disorders, Tenoten was prescribed 1 tablet 3 times a day, in the group with pre-neurotic conditions - 1 tablet 1-2 times a day, treatment duration - 2 weeks. A classification of premorbid disorders and a technique for early detection of premorbid mental health disorders using a screening questionnaire were used. Changes in anxiety levels and quality of life were assessed. All patients complained of a feeling of anxiety and restlessness of a transient nature, a feeling of tension, the inability to relax and determine the importance of work, decreased ability to work, attention, and mood; somatic and vegetative manifestations aggravated the condition and disrupted the usual rhythm of activity. By the end of the first week, during therapy with Tenoten, positive dynamics of the condition were noted: a decrease in anxiety and asthenic manifestations, a decrease in mnestic difficulties, and an increase in the speed of switching attention. During the second week, vegetative manifestations stabilized, general well-being improved, interpersonal relationships were restored, productivity and mood increased, a desire for active activity appeared, an increase in the level of quality of life was noted, and a continued decrease in the level of anxiety. Thus, we can say that the drug Tenoten, which has thymoleptic and psychostimulating properties, is highly effective in the treatment of anxiety and asthenia in patients with neurotic disorders and preneurotic conditions [9].

Conclusion

Studies have shown the high effectiveness of the drug Tenoten (2 tablets 3 times a day, course 4 weeks) in the treatment of anxiety-depressive disorders and asthenic manifestations. By the end of the 1st week, a vegetative stabilizing effect of the drug was noted, after 2 weeks - an initial decrease in the level of anxiety, which reaches its maximum manifestation by the end of the 4th week from the date of Tenoten's prescription. In some cases (for example, stage I-II DEP), the course of treatment with Tenoten (2 tablets 3 times a day) can be extended to 8 weeks. If the drug is prescribed to elderly patients, the dose of Tenoten is reduced to 1 tablet 3 times a day, the duration of administration is 4 weeks. Thus, based on the analysis of studies on the effectiveness of the drug Tenoten, conducted in clinics of various profiles, final conclusions can be drawn.

In neurological patients (with functional and organic diseases of the central nervous system) with psychovegetative and dyscirculatory disorders, Tenoten has a vegetative stabilizing, pronounced anti-anxiety (comparable to the benzodiazepine anxiolytic - Phenazepam) and nootropic (improving cognitive functions) effect.
In complex therapy of patients with diseases of the cardiovascular system, Tenoten has a pronounced anti-anxiety effect (not inferior to benzodiazepine anxiolytics - Grandaxin and Clonazepam) and increases the effectiveness of treatment, promoting a more rapid decrease in blood pressure, normalization of heart rate and a decrease in the frequency of angina attacks.
In the complex therapy of diseases of the digestive tract, Tenoten, in addition to a significant reduction in anxiety and depressive symptoms, helps to stabilize autonomic homeostasis, which leads to a decrease in the severity of clinical symptoms (reduction of dyskinetic phenomena, pain intensity, healing of ulcerative defects, etc.) and consolidation of remission. Overall, this significantly increases the effectiveness of treatment, reduces the time required for recovery and improves the quality of life of patients.
The pharmacotherapeutic value of Tenoten increases significantly due to the absence of side effects and the likelihood of developing dependence on the drug, which is extremely important for patients with both neurological and somatic profiles.
In the treatment of pre-neurotic and neurotic disorders, Tenoten simultaneously has an anti-anxiety and asthenic effect, helps stabilize vegetative manifestations, reduce mnestic difficulties (increases the speed of attention switching), which generally improves overall well-being and improves the quality of life of patients.

Why does not it work

Well, patamushta. This is homeopathy and, according to Zhukov’s precepts, “homeopathy cannot have evidence of effectiveness.”

Marketers, of course, are cunning: they don’t write anywhere that this is a homeopathic or at least a release-active drug. But let’s look at the composition: the active ingredient is affinity-purified antibodies to the brain-specific protein S100. The content per tablet is 0.003 grams. And then an awkward asterisk explaining that these 0.003 grams are applied to lactose in the form of a water-alcohol mixture containing no more than 10-15 ng/g of the active form of the active substance. Ng is a nanogram, or one billionth of a gram.

This means that in one tablet there are 3 × 10-27, or 0.0000000000000000000000000003 grams of active substance. In short, all these zeros here mean that there is not even a single seedy atom of this substance in the tablet. All that remains is sugar, onto which the magic mixture (aka water) has been dripped.

You know what else it's all about... Antibodies are large proteins that, ahem kek lol, do not pass through the blood-brain barrier, a kind of fence between the circulatory and nervous systems of the brain, the task of which is not to let any crap through (because the brain is a particularly valuable organ) . So even if the developers were worthy of providing at least one molecule per tablet, it simply would not reach these brain-specific proteins. That's it, curtain.

Tenoten is a sedative and anti-anxiety homeopathic drug based on affinity purified antibodies to the brain-specific protein S-100. Manufacturer: NPF Materia Medica Holding (Russia). The modern rhythm of life involves an abundance of stressful situations that await a person at work and at home. Constant psycho-emotional stress can negatively affect your health. The drug Tenoten will help rid the body of excessive stress load. It harmonizes nervous activity, has an anxiolytic (anti-anxiety) effect, supported by nootropic and vegetotropic effects. It is important that Tenoten does not cause drowsiness or decreased muscle tone. The drug helps the body cope with psycho-emotional overload, exhibits stress-protective, anti-asthenic, anti-amnestic, neuroprotective, anti-hypoxic and antidepressant effects. In conditions of oxygen starvation, intoxication, acute circulatory disorders of the brain, it localizes the source of damage and normalizes cognitive functions. Suppresses oxidative (free radical) degradation of lipids. Controls the functional activity of the marker of damage to the central nervous system - a specific protein of astrocytic glia S-100, which synchronizes synaptic and metabolic processes in the brain. An important property of the drug is its stress-protective effect. Tenoten increases the body's resistance to psycho-emotional stress, acts as an anxiolytic, eliminating increased anxiety and restlessness, and restores the plasticity of the central nervous system. Thanks to the drug, the patient becomes less sensitive to negative exogenous stimuli and becomes optimistic. Tenoten is effective for sudden mood changes, increased irritability, weakened cognitive functions (memory impairment, attention disorder), autonomic disorders associated with traumatic effects on the brain or damage to cerebral vessels.

When using Tenoten as part of a course of drug therapy, patients experienced a halving of anxiety levels. The vegetotropic effect of Tenoten lies in its ability to modulate blood pressure, heart rate and other autonomic reactions (increased breathing, dizziness, chills). The use of the drug in complex therapy allows you to normalize the tone of the autonomic nervous system by the end of the first week. Tenoten in combination with psychotherapy has a pronounced nootropic and anti-asthenic effect: it increases vitality and tolerance to mental and physical stress, strengthens memory, and improves attention.

Tenoten is available in tablet form. Single dose – 1 tablet. Frequency of application – 1-3 times a day. Directions for use: dissolution in the mouth. The tablet can be dissolved in a small amount of water. Eating and taking the drug should be spaced out in time. The duration of drug therapy is 1-3 months with the possibility of extending it up to six months. Repeated therapeutic courses are allowed at intervals of 1-2 months. The lack of stable improvement in the patient's condition after 3-4 weeks of regular pharmacotherapy is the basis for contacting a doctor to adjust the treatment. The drug does not have any undesirable side effects provided the recommended doses are followed. Theoretically, the possibility of individual intolerance to the active component of Tenoten is possible.